Prognostic factors in patients with gastric adenocarcinoma using competing-risk analysis: a study of cases in the SEER database

References

• Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.
   PubMed Web of Science ®Google Scholar
• Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat Database: Incidence – SEER 9 Regs Research Data, Nov 2010 Sub (1973–2008) <Katrina/Rita Population Adjustment> – Linked To County Attributes – Total U.S., 1969–2009 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Cancer Statistics Branch, released April 2011, based on the November 2010 submission.
   Google Scholar
• Jemal A, Siegel R, Xu J, et al. Cancer Statistics, 2010. CA Cancer J Clin. 2010;60:277–300.
   PubMed Web of Science ®Google Scholar
• You WC, Li JY, Zhang L, et al. Etiology and prevention of gastric cancer: a population study in a high risk area of China. Chin Dig Dis. 2005;6:149–154.
   PubMedGoogle Scholar
• Lambert R. Endoscopy in screening for digestive cancer. World J Gstrointest Endosc. 2012;4:518–525.
   Google Scholar
• Yaghoobi M, Bijarchi R, Narod SA. Family history and the risk of gastric cancer. Br J Cancer. 2010;102:237–242.
   PubMed Web of Science ®Google Scholar
• Ren JS, Kamangar F, Forman D, et al. Pickled food and risk of gastric cancer – a systematic review and meta-analysis of English and Chinese literature. Cancer Epidemiol Biomarkers Prev. 2012;21:905–915.
   PubMed Web of Science ®Google Scholar
• Cogliano VJ, Baan R, Straif K, et al. Preventable exposures associated with human cancers. J Natl Cancer Inst. 2011;103:1827–1839.
   PubMed Web of Science ®Google Scholar
• Yan B, Cui M, You J, et al. Gastric adenocarcinoma is concurrent with metastatic neuroendocrine cancer treated with nivolumab and chemotherapy: a case report. Mol Clin Oncol. 2018;9:607–612.
   PubMed Web of Science ®Google Scholar
• Nashimoto A, Akazawa K, Isobe Y, et al. Gastric cancer treated in 2002 in Japan: 2009 annual report of the JGCA nationwide registry. Gastric Cancer. 2013;16:1–27.
   PubMed Web of Science ®Google Scholar
• Cenitagoya GF, Bergh CK, Klinger-Roitman J. A prospective study of gastric cancer. ‘Real’ 5-year survival rates and mortality rates in a country with high incidence. Dig Surg. 1998;15:317–322.
   PubMed Web of Science ®Google Scholar
• Gunderson LL. Gastric cancer–patterns of relapse after surgical resection. Semin Radiat Oncol. 2002;12:150–161.
   PubMed Web of Science ®Google Scholar
• Ashraf N, Hoffe S, Kim R. Adjuvant treatment for gastric cancer: chemotherapy versus radiation. Oncologist. 2013;18:1013–1021.
   PubMed Web of Science ®Google Scholar
• Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transplant. 2007;40:381–387.
   PubMed Web of Science ®Google Scholar
• Kim HT. Cumulative incidence in competing risks data and competing risks regression analysis. Clin Cancer Res. 2007;13(2 Pt 1):559–565.
   PubMed Web of Science ®Google Scholar
• National Cancer Institute. Surveillance, Epidemiology and End Results 2014. Cancer. 2014;120:3755–3757.
   PubMedGoogle Scholar
• Liu C, Zhao Q, Li Z, et al. Mixed subtype thyroid cancer: a surveillance, epidemiology, and end results database analysis. Oncotarget. 2017;8:86556–86565.
   PubMedGoogle Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc. 1999;94:496–509.
   Web of Science ®Google Scholar
• Austin PC, Fine JP. Practical recommendations for reporting Fine-Gray model analyses for competing risk data. Stat Med. 2017;36:4391–4400.
   PubMed Web of Science ®Google Scholar
• Lau B, Cole SR, Gange SJ. Competing risk regression models for epidemiologic data. Am J Epidemiol. 2009;170:244–256.
   PubMed Web of Science ®Google Scholar
• Ahmad A, Khan H, Cholankeril G, et al. The impact of age on nodal metastases and survival in gastric cancer. J Surg Res. 2016;202:428–435.
   PubMed Web of Science ®Google Scholar
• Costa M, Ribeiro K, Machado M, et al. Prognostic score in gastric cancer: the importance of a conjoint analysis of clinical, pathologic, and therapeutic factors. Ann Surg Oncol. 2006;13:843.
   PubMed Web of Science ®Google Scholar
• Liu L, Hao H, Zhao L, et al. Analysis of survival and prognosis of 298 gastric adenocarcinoma patients with no distant metastasis. Oncol Lett. 2017;14:7813–7816.
   PubMed Web of Science ®Google Scholar
• Yu J-W, Wu J-G, Zheng L-h, et al. Influencing factors and clinical significance of the metastatic lymph nodes ratio in gastric adenocarcinoma. J Exp Clin Cancer Res. 2009;28:1–7.
   PubMed Web of Science ®Google Scholar
• Songun I, Putter H, Kranenbarg EM, et al. Surgical treatment of gastric cancer: 15-year follow-up results of the randomised nationwide Dutch D1D2 trial. Lancet Oncol. 2010;11(5):439–449.
   PubMed Web of Science ®Google Scholar
• Deng J, Liang H, Wang D, Sun D, Pan Y, Liu Y. Investigation of the recurrence patterns of gastric cancer following a curative resection. Surg Today. 2011;41:210.
   PubMed Web of Science ®Google Scholar
• Rice TW, Patil DT, Blackstone EH. 8th edition AJCC/UICC staging of cancers of the esophagus and esophagogastric junction: application to clinical practice. Ann Cardiothorac Surg. 2017;6:119–130.
   PubMed Web of Science ®Google Scholar
• Jun K-H, Lee J-S, Kim J-H, et al. The rationality of N3 classification in the 7th edition of the International Union Against Cancer TNM staging system for gastric adenocarcinomas: a case-control study. Int J Surg. 2014;12:893–896.
   PubMed Web of Science ®Google Scholar
• Kelly KJ, Selby L, Chou JF, et al. Laparoscopic versus open gastrectomy for gastric adenocarcinoma in the West: a case-control study. Ann Surg Oncol. 2015;22:3590–3596.
   PubMed Web of Science ®Google Scholar
• De Vita F, Vecchione L, Galizia G, et al. Perspectives in adjuvant therapy of gastric cancer. Oncology. 2009;77:38.
   PubMed Web of Science ®Google Scholar
• Khosravi Shahi P, Díaz Muñoz de la Espada V, García Alfonso P, et al. Management of gastric adenocarcinoma. Clin Transl Oncol. 2007;9:438.
   PubMed Web of Science ®Google Scholar
• Gabriel E, Attwood K, Narayanan S, et al. Does neoadjuvant/perioperative chemotherapy improve overall survival for T2N0 gastric adenocarcinoma? J Surg Oncol. 2018;117:659–670.
   PubMed Web of Science ®Google Scholar
• Huang ZN, Chen QY, Zheng CH, et al. Are the indications for postoperative radiotherapy in the NCCN guidelines for patients with gastric adenocarcinoma too broad? A study based on the SEER database. BMC Cancer. 2018;18:1064.
   PubMed Web of Science ®Google Scholar
• Noone AM, Lund JL, Mariotto A, et al. Comparison of SEER treatment data with medicare claims. Med Care. 2016;54:e55–e64.
   PubMed Web of Science ®Google Scholar
• Navi BB, Reiner AS, Kamel H, et al. Risk of arterial thromboembolism in patients with cancer. J Am Coll Cardiol. 2017;70:926–938.
   PubMed Web of Science ®Google Scholar
• Bolch CA, Chu H, Jarosek S, et al. Inverse probability of treatment-weighted competing risks analysis: an application on long-term risk of urinary adverse events after prostate cancer treatments. BMC Med Res Methodol. 2017;17:93.
   PubMed Web of Science ®Google Scholar
• Carmona R, Zakeri K, Green G, et al. Improved method to stratify elderly patients with cancer at risk for competing events. J Clin Oncol. 2016;34:1270–1277.
   PubMed Web of Science ®Google Scholar
• Satkunasivam R, Kim AE, Desai M, et al. Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol. 2015;194:378–385.
   PubMed Web of Science ®Google Scholar
• Carmona R, Gulaya S, Murphy JD, et al. Validated competing event model for the stage I-II endometrial cancer population. Int J Radiat Oncol Biol Phys. 2014;89:888–898.
   PubMed Web of Science ®Google Scholar